Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD‐NP, in a First‐in‐Human Clinical Trial in Healthy Subjects
Why the study?
Does CD-NP possess cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension in normal human volunteers?
Population
Normal human volunteers
Design
Other
Authors
Discussion
Loading...
Member takes
Implication
Supports evaluation in heart failure; leaves open efficacy and safety in patients.
Structured PICO
Does CD-NP possess cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension in normal human volunteers?
P
Population
Normal human volunteers
I
Intervention
CD-NP (a novel chimeric natriuretic peptide)
O
Outcome
Cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties, and blood pressure effectssurrogate
First-in-human testing of CD-NP demonstrates favorable pharmacodynamic properties, including cGMP activation and natriuresis without excessive hypotension, supporting further investigation in heart failure.
Cite This Study
Lee et al. (2009) studied this question.